GlassScriptPhysician profile
Pamela Cramer
NPI 1487129243
$4,116.12
in general payments reported to CMS, 2019-2025
43 companies · $905 in 2025
The $905 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $887 · 2022: $741 · 2023: $876 · 2024: $707 · 2025: $905.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,313 · Consulting Fee: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,313.10 |
| Consulting Fee | $175.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,052.69 | 2021-2025 | |
| Amgen INC. | $350.03 | 2021-2025 | Prolia, Evenity, Prolia |
| Astrazeneca Pharmaceuticals LP | $247.00 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $196.37 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Novartis Pharmaceuticals Corporation | $143.83 | 2022-2024 | |
| Otsuka America Pharmaceutical, INC. | $140.04 | 2021-2025 | Rexulti |
| Axsome Therapeutics, INC. | $133.57 | 2023-2025 | Auvelity, Symbravo |
| Pfizer INC. | $131.84 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $124.17 | 2021 | |
| Alkermes, INC. | $123.59 | 2022-2025 | Aristada, Lybalvi |
| Corium, LLC | $123.00 | 2023 | Azstarys |
| Lilly USA, LLC | $109.75 | 2021-2025 | Jardiance, Zepbound, Emgality |
| Glaxosmithkline, LLC. | $104.39 | 2021-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Biohaven Pharmaceutical Holding Company LTD. | $93.68 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $74.56 | 2021-2022 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pamela Cramer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.